Coherus OncologyvsThermo Fisher Scientific

CHRS and TMO stock compared: price, dividend, valuation and results, from SEC filings.

CHRS

Coherus Oncology, Inc.

$0.51

Value $77M

-2.47%
CHRS's page

TMO

Thermo Fisher Scientific Inc

$691.85

Value $257B

-1.29%
TMO's page

Coherus Oncology (CHRS) has a market value of $77M and Thermo Fisher Scientific (TMO) $257B. Over the last year, with dividends, CHRS moved -56.9% and TMO +20.0%. Dividend yield: CHRS none, TMO 0.27%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    CHRS$77M

    TMO$257B

    TMO is 3,342 times CHRS

  • Revenue, 12 months

    CHRS$54M

    TMO$47.4B

    TMO is 883 times CHRS

  • Net income, 12 months

    CHRS-$136M

    TMO$7.1B

  • Operating margin

    CHRS-275.9%

    TMO17.9%

    293.8 points apart

  • ROIC

    CHRS-186.5%

    TMO8.2%

    194.7 points apart

  • P/E

    CHRS–

    TMO36.3

  • Dividend yield

    CHRS0.0%

    TMO0.3%

    0.3 points apart

  • 5-year return

    CHRS-97.3%

    TMO+11.0%

    108.3 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

CHRS-97.3%

TMO+11.0%

05010020222023202420252026
Returns by period
PeriodCHRSWith dividendsTMOWith dividends
1 year since November 14, 2025-56.9%Price -56.9%+20.0%Price +19.6%
3 years since November 16, 2023-70.0%-33.1% a yearPrice -70.0%+47.9%+13.9% a yearPrice +46.4%
5 years since November 15, 2021-97.3%-51.4% a yearPrice -97.3%+11.0%+2.1% a yearPrice +9.4%
10 years since November 16, 2016-98.1%-32.9% a yearPrice -98.1%+376.1%+16.9% a yearPrice +362.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

CHRSCoherus OncologyTMOThermo Fisher Scientific

Valuation

CHRSTMO
Valuation
Price$0.51$691.85
Market value$77M$257B
Enterprise value (EV)–$292B
P/E–36.3
P/E, 5-year median–32.7
P/B3.14.7
EV/EBIT–34.5
Free cash flow yield–3.0%

Results and growth

CHRSTMO
Results and growth
Revenue, 12 months$54M$47.4B
Net income, 12 months-$136M$7.1B
Free cash flow, 12 months-$174M$7.6B
Earnings per share, 12 months-$1.00$18.96
Revenue growth, year on year59.8%3.9%
Revenue growth a year, past-38.4%over 5 years+6.7%over 5 years
EPS growth a year, past-2.5%over 5 years+2.1%over 5 years

Margins and returns on capital

CHRSTMO
Margins and returns on capital
Gross margin69.8%–
Operating margin-275.9%17.9%
Net margin-253.4%14.9%
ROIC-186.5%8.2%
ROE-216.8%13.4%

Balance sheet

CHRSTMO
Balance sheet
Cash$84M$6.1B
Total debt–$41.4B
Net debt / EBITDA–3.7
Interest cover-15.5×5.5×

Dividends and buybacks

CHRSTMO
Dividends and buybacks
Dividend yield–0.3%
Dividend per share, 12 months–$1.84
Dividend growth a year, past–+14.3%over 5 years
Buyback yield–1.2%
Shareholder yield–1.4%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: CHRS or TMO

Didn't find what you were looking for?

Ask us
Which is bigger, Coherus Oncology or Thermo Fisher Scientific?

By market value, Thermo Fisher Scientific ($257B) is about 3,342.4 times Coherus Oncology ($77M), at today's prices.

How did CHRS and TMO stock do over the last 10 years?

Since November 16, 2016, CHRS's price moved -98.1% and TMO's +362.8%. With dividends: CHRS -98.1% (-32.9% a year), TMO +376.1% (+16.9% a year). Past returns do not predict future ones.

Which pays the higher dividend, CHRS or TMO?

The dividend yield at today's price is none for Coherus Oncology and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.

Which has the higher profit margins, Coherus Oncology or Thermo Fisher Scientific?

Over the last twelve months, the net margin was -253.4% for Coherus Oncology and 14.9% for Thermo Fisher Scientific, and the operating margin -275.9% and 17.9%. Revenue was $54M and $47.4B.

Which is the better investment, Coherus Oncology or Thermo Fisher Scientific?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.